cm214_pfs: Sample Reconstructed Data of CheckMate214 Study

In survRM2adapt: Flexible and Coherent Test/Estimation Procedure Based on Restricted Mean Survival Times

Sample Reconstructed Data of CheckMate214 Study

Description

The progression-free survival data reconstructed from the publication of the CheckMate214 study.

Usage

data(cm214_pfs)

Format

A dataset containing 3 columns:

time

the time-to-event variable (the time unit is month)

status

the event indicator (1=event, 0=censor)

arm

the treatment indicator (1=treatment, 0=control)

Details

This is a reconstructed patient-level data from the results reported by Motzer et al.(2018) <doi:10.1056/NEJMoa1712126>. The data consists of 847 patients with previously untreated clear-cell advanced renal-cell carcinoma; 425 for the nivolumab plus ipilimumab group (treatment) and 422 for the sunitinib group (control).

Source

Motzer RJ, Tannir NM, McDermott DF, et al. Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma. New England Journal of Medicine. 2018;378(14):1277-1290. <doi:10.1056/NEJMoa1712126> Guyot P, Ades AE, Ouwens MJ, Welton NJ. Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves. BMC Med Res Methodol. 2012;12(1):9. <doi:10.1186/1471-2288-12-9>

survRM2adapt documentation built on March 31, 2023, 7:15 p.m.